Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Li-kun Chen · 2024
ClinicalTrials.gov · Datasets · License: Public Domain · 2024
Open Source ↗
non-small cell lung cancer (nsclc), egfr mutation-positive lung cancer, brain metastases, leptomeningeal metastases, intracranial tumor progression, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 889382
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.